Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease
Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease
复制标题
DOI：
10.1001/archneur.57.1.100
复制
发表时间：
2000-01-01
影响因子：
--
通讯作者：
Wisniewski, HM
中科院分区：
文献类型：
--
作者：
Mehta, PD;Pirttilä, T;Wisniewski, HM
背景：在阿尔茨海默病患者的大脑中，Aβ是弥漫斑块的主要成分。已有报道显示AD患者脑脊液Aβ42水平低于正常对照组。尽管研究表明家族性AD患者的血浆Aβ42水平较高，但最近的一份报告表明，散发性AD组和对照组的血浆Aβ42水平相似。然而，目的：检测疑似阿尔茨海默病(AD)患者和老年非痴呆对照组血浆和脑脊液中淀粉样β蛋白1-40(Aβ40)和1-42(Aβ42)水平与载脂蛋白E(Apo E)基因和痴呆严重程度的关系。背景：两所大学医学中心。患者和方法：测定78例AD患者血浆和脑脊液中Aβ40和Aβ42水平。结果：AD组血浆Aβ40平均水平明显高于对照组(P=0.005)；但两者之间有很大的重叠；Aβ42水平在两组之间相似。Aβ40和Aβ42的水平与性别或简明精神状态检查分数无关。在对照组中，年龄与Aβ40水平显著相关，而在AD组中，年龄与Aβ40水平无关。携带Apo E epsilon 4等位基因的AD患者的Aβ40水平高于对照组(P<0.01)。AD组和对照组的脑脊液Aβ40水平相似。然而，AD组的Aβ42水平低于对照组(P<；.001)。结论：虽然散发性阿尔茨海默病患者血浆Aβ40水平升高，且受载脂蛋白E基因分型的影响，但检测血浆Aβ40水平不能作为AD的临床诊断依据。AD组较低的脑脊液Aβ42水平与以前的研究一致。
Background: In brains with AD, A beta is a major component of diffuse plaques. Previous reports showed that CSF A beta 42 levels were lower in patients with AD than in controls. Although studies showed higher plasma A beta 42 levels in familial AD, a recent report has indicated that plasma A beta 42 levels were similar in a sporadic AD group and controls. However, no information is published on plasma A beta 40 and A beta 42 levels in relation to Apo E genotype or severity of dementia in sporadic AD.Objective: To examine plasma and cerebrospinal fluid (CSF) levels of amyloid beta protein 1-40 (A beta 40) and 1-42 (A beta 42) levels in patients with probable Alzheimer disease (AD) and elderly nondemented control subjects in relation to the apolipoprotein E (Apo E) genotype and dementia severity.Setting: Two university medical centers.Patients and Methods: Levels of A beta 40 and A beta 42 were measured in plasma from 78 patients with AD and 61 controls and in CSF from 36 patients with AD and 29 controls by means of a sandwich enzyme-linked immunosorbent assay.Results: Mean plasma A beta 40 levels were higher in the AD group than in controls (P = .005), but there was substantial overlap; A beta 42 levels were similar between the groups. Levels of A beta 40 and A beta 42 showed no association with sex or Mini-Mental State Examination scores. There was a significant relationship between age and A beta 40 level in controls but not in the AD group. Levels of A beta 40 were higher in patients with AD with the Apo E epsilon 4 allele than in controls (P < .01). Cerebrospinal fluid A beta 40 levels were similar in the AD group and controls. However, A beta 42 levels were lower in the AD group than in controls (P < .001). The levels showed no association with severity of dementia.Conclusions: Although mean plasma A beta 40 levels are elevated in sporadic AD and influenced by Apo E genotype, measurement of plasma A beta 40 levels is not useful to support the clinical diagnosis of AD. Lower levels of CSF A beta 42 in the AD group are consistent with previous studies.